Phuturdex › Diseases › Colorectal Neoplasms, Hereditary Nonpolyposis
Drugs in development · updated 30 October 2026
Colorectal Neoplasms, Hereditary Nonpolyposis: drugs in development
As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 12 drugs for colorectal Neoplasms, Hereditary Nonpolyposis. 2 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Acetylsalicylic acid lysinate | III | 1 | NCT02813824 |
| VVD-133214 | II | 1 | NCT07811193 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AtezolizumabTecentriq, MPDL3280A | III | 1 | NCT02912559 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT02912559 |
| LeucovorinFolinic acid, l-leucovorin | III | 1 | NCT02912559 |
| OxaliplatinOxaliplatine, Oxaliplain | III | 1 | NCT02912559 |
| SecretinSecretin-Ferring® | III | 1 | NCT02000089 |
| PembrolizumabKEYTRUDA, MK-3475 | II | 2 | NCT07811193 |
| AspirinVazalore®, Durlaza® | II | 1 | NCT05411718 |
| Mesalaminemesalazine, Delzicol® | II | 1 | NCT04920149 |
| NaproxenNaprelan®, Aleve® | II | 1 | NCT05411718 |
| Nogapendekin Alfa | II | 1 | NCT05419011 |
Sorted by most advanced phase and number of active trials.
All 12 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Anaplastic large-cell lymphoma 36 drugs
- Extramammary Paget's disease 13 drugs
- Merkel cell carcinoma 48 drugs
- T-cell lymphoma 74 drugs
- Mycosis fungoides 40 drugs
- Cutaneous T cell lymphoma 46 drugs
- Sezary Syndrome 30 drugs
- Signet ring cell adenocarcinoma 4 drugs
- Basal-cell carcinoma of the skin 28 drugs
Broader categories
- Neoplasm 671 drugs
- Digestive System Diseases 36 drugs
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Digestive system neoplasm 37 drugs
- Intestinal neoplasm 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D003123 “Colorectal Neoplasms, Hereditary Nonpolyposis”.